Skip to main content

Table 1 Demographics and tumor information for primary and second tumors stratified by progesterone receptor (PR) status

From: ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors

Group

Primary tumor

Second tumor

(1) PR+ to PR+ (n = 10)

 Age (±SD), range

53.8 (±16.9), 37–84

61.4 (±16.7), 40–90

 Tumor type

DCIS 1; IDC 8; ILC 1

DCIS 1; IDC 7; ILC 2

 Hormonal therapy

Yes = 10 (6 tamoxifen, 4 type unknown)

(2) PR+ to PR− (n = 6)

 Age (±SD), range

54 (±7.8), 42–62

63.3 (±7.1), 55–74

 Tumor type

DCIS 1; IDC 3; ILC 1; IDC and ILC 1

DCIS 2; IDC 3; ILC 1

 Hormonal therapy

Yes = 6 (4 tamoxifen, 2 aromatase inhibitor)

(3) PR− to PR− (n = 8)

 Age (±SD), range

60.1 (±10.6), 46–79

63.3 (±11.1), 48–80

 Tumor type

DCIS 1; IDC 7

DCIS 1; IDC 7

 Hormonal therapy

No = 5; Yes = 3 (all tamoxifen)

  1. DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma